The price of follistatin peptid reagents in academic and industrial laboratories varies based on isoform complexity, expression host, purification rigor, and lot-specific analytical validation. High-grade research follistatin requires stringent quality controls—including mass spectrometry verification and low endotoxin thresholds—to ensure experimental reproducibility in cellular and animal models.
The price of follistatin peptid reagents in academic and industrial laboratories varies based on isoform complexity, expression host, purification rigor, and lot-specific analytical validation. High-grade research follistatin requires stringent quality controls—including mass spectrometry verification and low endotoxin thresholds—to ensure experimental reproducibility in cellular and animal models.
When evaluating the price of follistatin peptid compounds for experimental use, principal investigators must account for several biochemical and manufacturing variables. Follistatin is a structurally complex, cysteine-rich glycoprotein that contains multiple intrachain disulfide bonds. Synthesizing or expressing this protein with correct tertiary folding requires sophisticated biotechnology infrastructure, directly influencing the final unit cost of laboratory-grade reagents.
Pricing structure is heavily dictated by the specific variant under study. For instance, Follistatin 344 and Follistatin 315 differ in C-terminal sequence length and heparin-binding characteristics, which alter their solubility and biochemical handling requirements. Furthermore, peptides produced via recombinant bacterial systems often require extensive refolding procedures to establish biological activity, whereas mammalian cell line expression systems yield native glycosylation patterns at higher baseline production costs.
Budget planning for cell culture or preclinical animal research must also account for analytical verification. Low-cost vendors frequently omit comprehensive characterization, whereas accredited domestic suppliers incorporate lot-specific High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) testing into their baseline pricing, ensuring that experimental results are not compromised by truncated sequences or heavy metal contamination.
Follistatin functions primarily as an endogenous antagonist of specific members of the Transforming Growth Factor-beta (TGF-β) superfamily. In preclinical literature, its primary regulatory target is activin A, a dimeric protein involved in reproductive physiology, cellular differentiation, and systemic inflammatory cascades. Follistatin binds activin with high affinity, effectively neutralising its interaction with cell-surface serine/threonine kinase receptors.
In addition to activin neutralization, in vitro assays demonstrate that follistatin binds and inhibits Myostatin (Growth Differentiation Factor 8, or GDF-8) and GDF-11. Structurally, the binding mechanism involves a stoichiometric ratio of two follistatin molecules surrounding one dimeric TGF-β ligand. This interaction buries the receptor-binding sites of the ligand, blocking signal transduction through the ActRIIB (Activin Receptor Type IIB) signaling complex.
Because of its broad regulatory footprint across the TGF-beta superfamily signaling pathway, researchers utilize follistatin as a baseline tool to study muscle hypertrophy mechanisms, fibrosis inhibition, and metabolic homeostasis in controlled laboratory environments.
Preclinical investigation into follistatin variants has focused largely on skeletal muscle biology and regenerative medicine. In rodent models of muscle atrophy, transgenic overexpression or exogenous administration of follistatin peptides has been observed to promote marked hyperplastic and hypertrophic responses in myofibers. These changes occur due to the dual suppression of myostatin and activin signaling, which otherwise limit muscle mass accumulation.
In vitro data indicate that treating C2C12 myoblast cultures with recombinant follistatin increases the transcription of muscle-specific proteins while repressing the Smad2/3 phosphorylation downstream of ActRIIB activation. This mechanistic pathway makes follistatin a key reference compound in studies targeting sarcopenia, cachexia, and muscular dystrophies.
Beyond skeletal muscle research, investigators utilize follistatin to study tissue repair and fibrotic response mechanisms. Preclinical models of hepatic and pulmonary fibrosis suggest that neutralizing circulating activin A via follistatin administration can mitigate excessive extracellular matrix deposition, illustrating the compound's broad potential across diverse physiological systems.
A critical consideration when assessing the price of follistatin peptid orders is verifying that the material meets strict analytical benchmarks. Cheap market alternatives often contain sequence truncations, residual chemical reagents from solid-phase synthesis, or aggregated protein fractions that impair biological activity.
To ensure sample integrity, laboratory procurement standards require validation via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). Detailed analysis of the resulting spectra provides unambiguous confirmation of chemical identity and purity percentage:
RP-HPLC separation quantifies the relative concentration of the target peptide against synthesis byproducts or degradation species, establishing a baseline purity threshold (typically ≥95% or ≥98% for quantitative assays). Mass spectrometry validates the exact molecular weight, ensuring that the 344-amino-acid or 315-amino-acid sequence retains its expected primary structure. Researchers can review standard methodologies in our guide to peptide purity HPLC analysis.
For researchers conducting in vitro cell culture or sensitive in vivo assays, endotoxin contamination represents a major confounding variable. Bacterial endotoxins (lipopolysaccharides, or LPS) present in poorly purified recombinant peptides can trigger non-specific inflammatory responses, invalidating cell viability and gene expression data.
High-quality research-grade follistatin undergoes Limulus Amebocyte Lysate (LAL) testing to confirm low endotoxin levels, ideally below 0.01 EU/μg of protein. Facilities adhering to ISO 17025 standards and Good Manufacturing Practice (GMP) guidelines incorporate rigorous purification steps—such as anion-exchange chromatography and ultrafiltration—to remove pyrogens.
Purchasing unverified peptides to lower initial expenditure often results in costly experimental failures due to LPS-induced cell toxicity or aberrant cytokine expression in baseline controls. Verifying lot-specific Certificate of Analysis (COA) documents prior to purchasing safeguards institutional research budgets.
When designing protocols to investigate muscle regulatory pathways or TGF-β signaling, researchers frequently compare follistatin against alternative pathway antagonists. Understanding the mechanistic differences between these compounds helps clarify project-specific reagent selection and budget allocations.
The TGF-β regulatory axis can be targeted via direct ligand neutralization, receptor blockade, or downstream signaling modification. For instance, researchers evaluating hypertrophic signalling mechanisms often compare Follistatin 344 with Bimagrumab, a monoclonal antibody designed to bind directly to ActRIIA/B receptors rather than sequestering free ligands. In parallel protocols examining downstream metabolic shifts and protein synthesis, researchers may also incorporate IGF-1 DES to assess receptor-tyrosine kinase crosstalk alongside myostatin suppression.
Unlike selective receptor antibodies, follistatin binds multiple ligands with high affinity. This broader spectrum of activity makes it a uniquely powerful tool for comprehensive pathway suppression studies, though it requires careful experimental control to isolate specific ligand-receptor dynamics.
To preserve structural integrity and prevent degradation, lyophylized follistatin must be handled according to strict physical parameters. Upon receipt, freeze-dried peptide vials should be stored at -20°C or -80°C in a desiccated environment away from ambient light.
Reconstitution protocols require sterile, endotoxin-free solvents. Standard procedure involves dissolving the lyophilized powder in sterile bacteriostatic water or phosphate-buffered saline (PBS). For long-term storage of reconstituted stock solutions, adding a carrier protein such as 0.1% Bovine Serum Albumin (BSA) helps prevent nonspecific adsorption of the follistatin peptide to glass or plastic vessel walls.
Repeated freeze-thaw cycles must be avoided, as physical shear stress causes irreversible protein denaturation and aggregation. Reconstituted aliquots should be portioned into single-use volumes and stored at -80°C, maintaining stability for multi-week cell culture series or long-term animal trials.
Procuring research peptides requires systematic vetting of supplier quality control systems. A reliable vendor must provide transparent, lot-specific documentation for every batch of follistatin peptide supplied to academic, biotech, or pharmaceutical laboratories.
Essential verification documents include:
1. Certificate of Analysis (COA) displaying real chromatograms and mass spectra, not static template documents. 2. Quantification of sequence identity, purity percentage, and net peptide content. 3. Endotoxin assay results validating suitability for cell culture work. 4. Documentation of US-based manufacturing standards and ISO 17025 accredited testing facilities.
Establishing a direct line with an accredited supplier ensures batch-to-batch consistency across extended research projects. For institutional procurement requirements, researchers can explore custom quantities and laboratory account tiers via our wholesale procurement program.
Navigating the price of follistatin peptid reagents requires balancing immediate lab budget constraints against long-term data validity and experimental repeatability. Investing in fully verified, low-endotoxin research compounds minimizes experimental noise and protects cell lines from artifactual signaling responses.
PX1 Research maintains rigorous quality protocols for all catalog reagents, supporting academic and corporate laboratories with fully documented peptides synthesized under strict quality controls. Researchers can explore our full catalog of research compounds in the PX1 Research Library Hub or review individual specifications on our all peptides catalog.
What factors primary determine the price of follistatin peptid reagents?
Pricing is governed by sequence length (e.g., FS-344 vs FS-315), synthesis methodology (recombinant expression vs complex solid-phase synthesis), multi-step purification complexity, and the extent of third-party analytical testing (HPLC, MS, LAL endotoxin testing).
What is the difference between Follistatin 344 and Follistatin 315?
Follistatin 344 is a precursor protein that undergoes C-terminal truncation to form mature isoforms such as Follistatin 315. In research settings, FS-344 is often studied for its tissue distribution, whereas FS-315 represents the predominant circulating isoform with distinct heparin-binding domain interactions.
Why is third-party COA verification critical for follistatin research?
Follistatin is a cysteine-rich peptide with complex folding requirements. A third-party COA containing RP-HPLC and mass spectrometry data confirms that the sample has correct disulfide mapping, high chemical purity, and freedom from truncated sequence contaminants.
What endotoxin levels are acceptable for in vitro follistatin experiments?
For cell culture assays, endotoxin levels should ideally be below 0.01 EU/μg. High endotoxin levels induce inflammatory pathways in cells, creating experimental noise that interferes with target signaling measurements.
How should reconstituted follistatin be stored in the laboratory?
Reconstituted follistatin should be diluted in sterile buffer (PBS or water) with 0.1% BSA to prevent vessel adsorption, divided into single-use aliquots, and stored at -80°C. Repeated freeze-thaw cycles must be avoided.
Is follistatin suitable for human administration?
No. All follistatin compounds supplied by PX1 Research are strictly intended for laboratory research use only (in vitro and animal model investigation) and are not for human consumption, clinical treatment, or diagnostic use.
How does follistatin compare to bimagrumab in myostatin research?
Follistatin works by directly sequestering circulating ligands (activin A, myostatin, GDF-11), preventing them from reaching receptors. Bimagrumab is a monoclonal antibody that competitively blocks the ActRIIB receptor itself.
Where are PX1 Research peptides manufactured and tested?
PX1 Research peptides are manufactured in US-based GMP-compliant facilities and undergo independent analytical testing at ISO 17025 accredited laboratories with lot-specific COAs provided.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.